On October 30, 2017, VBI Vaccines Inc. (“VBI”) completed its underwritten public offering of 16,100,000 common shares and concurrent registered direct offering of 7,475,410 common shares. Aggregate gross proceeds from the public offering and registered direct offering, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately US$71.9 million. VBI is a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines listed on the NASDAQ Capital Market (VBIV) and the Toronto Stock Exchange (VBV).
BMO Capital Markets and Canaccord Genuity acted as book-runners, and Ladenburg Thalmann acted as lead manager for the underwritten public offering.
The underwriters were represented in Canada by Georald Ingborg, Amanda Robinson and Samuel Li of Fasken Martineau.